Work Area: IP public policy

Latest content

Tillis’s 101 bill will rev the US innovation engine once again

Paul Michel, former Chief Judge of the US Court of Appeals for the Federal Circuit, and ex-USPTO Director David Kappos urge Congress to embrace legislation designed to repair patent eligibility law which they believe the US Supreme Court has distorted

06 August 2022

UK publishes SEP outreach responses, but no changes are imminent

Despite the increasing attraction of the London courts, the real FRAND focus in Europe is likely to be on EU action which is promised by the end of the year

05 August 2022

Tillis’s 101 reform bill wins plaudits despite flaws

The Patent Eligibility Restoration Act of 2022 effectively overturns Supreme Court precedent and provides greater clarity on eligibility but some believe it may require further work

03 August 2022

Brexit was my toughest challenge, says outgoing UK IP Office head

In an exclusive interview, Tim Moss talks through the five years he spent leading the agency and provides an update on its current study of SEP/FRAND policy issues

02 August 2022

Chinese invention patent grants up 16% in the first half of 2022

Domestic entities lead the charge, with authorities also keen to encourage further international filings

02 August 2022

WDTX judges on new random assignment list lack patent experience

Filing in Waco now seems a real gamble, as a deep dive on Docket Navigator reveals that most of Alan Albright’s colleagues have handled a relatively low number of cases

01 August 2022

IP tax strategies come under fire from US senators

Legislators put pharma companies under the microscope and blame a law signed by President Trump in 2017 for patent-based payment mitigation

01 August 2022

Tillis to introduce 101 reform legislation within weeks

“If we don’t fix this mess, and fix it soon, America isn’t going to be the global leader in innovation across multiple industries,” says senator in exclusive IAM interview

28 July 2022

Teva’s skinny label SCOTUS petition is a must-watch for generics

The move is the company’s final resort as it seeks to overturn a $235 million damages decision that has major IP implications for the entire pharmaceutical industry

28 July 2022

Vidal opens up on PTAB reform, 101 and SEPs in conference dialogue with Iancu

Speaking at an event in Washington DC, the USPTO Director expanded on challenges facing the agency, and how they may be addressed

27 July 2022

Unlock unlimited access to all IAM content